Stay updated with breaking news from Synapse Biomedical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oberlin-based Synapse Biomedical recently secured U.S. Food and Drug Administration premarket approval for its diaphragm pacing system for use in patients with spinal cord injuries (SCI) who rely on mechanical ventilation.
Synapse Biomedical has received premarket approval from the FDA for its NeuRx Diaphragm Pacing System, which aids adults with spinal cord injuries that require ventilation to breathe, according to a company press release.Using negative pressure ventilation, as opposed to positive pressure, the NeuRx device can imitate natural breathing and be used continuously for a minimum of 4 hours daily,
/PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®)...
The development of the breathing device, called the NeuRx diaphragm pacing system, has been 20 years in the making.
Visiongain has published a new report entitled Neurotech Devices Market 2023-2033. It includes profiles of Neurotech Devices and Forecasts, Market Segment...